Latest research on Zytiga

Abiraterone is a derivative of steroidal progesterone and is an innovative drug that offers clinical benefit to patients with hormone refractory prostate cancer. Abiraterone is administered as an acetate salt prodrug because it has a higher bioavailability and less susceptible to hydrolysis than abiraterone itself. FDA approved on April 28, 2011.

Zytiga indications

CYP17A1 inhibitors, such as abiraterone acetate (Zytiga), are sought as a potential effective therapy for castrate resistance prostate cancer [117, 119]. [source, 2015]
To determine the effect of NRs on PCa cell growth, androgen-sensitive (LNCaP) and -insensitive (PC-3, C4-2B) and castration-resistant (22Rv1) human prostate cancer cells were treated with NRs (VN/66-1, VNLG-145, -146, -147, -148, -152, -153), VN/14-1, ATRA, 4-HPR, Casodex, Abiraterone acetate (AA) (Zytiga) and MDV3100 (Enzalutamide) (Figure 1) and assessed for cell viability by MTT assay. [source, 2014]